Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Monopar Therapeutics announced its Q1 2026 financial results and provided updates on its late-stage ALXN1840 drug candidate for Wilson disease, including positive Phase 3 trial data and an on-track NDA submission planned for mid-2026. The company also highlighted commercial readiness led by new Chief Commercial Officer Susan Rodriguez and expects s…